Windtree Therapeutics - WINT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.30
▼ -0.04 (-11.76%)

This chart shows the closing price for WINT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Windtree Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WINT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WINT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Windtree Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.30.

This chart shows the closing price for WINT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Windtree Therapeutics. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021OppenheimerInitiated CoverageOutperform$8.00High
6/26/2020LADENBURG THALM/SH SHInitiated CoverageBuy$12.25Medium
(Data available from 10/2/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
4/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/5/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/2/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Windtree Therapeutics logo
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Read More

Today's Range

Now: $0.30
Low: $0.29
High: $0.33

50 Day Range

MA: $0.39
Low: $0.30
High: $0.70

52 Week Range

Now: $0.30
Low: $0.28
High: $2.37

Volume

2,164,583 shs

Average Volume

1,726,466 shs

Market Capitalization

$9.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Windtree Therapeutics?

The following Wall Street analysts have issued stock ratings on Windtree Therapeutics in the last year:
View the latest analyst ratings for WINT.

What is the current price target for Windtree Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Windtree Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Windtree Therapeutics in the next year.
View the latest price targets for WINT.

What is the current consensus analyst rating for Windtree Therapeutics?

Windtree Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for WINT.

What other companies compete with Windtree Therapeutics?

How do I contact Windtree Therapeutics' investor relations team?

Windtree Therapeutics' physical mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The company's listed phone number is (215) 488-9300 and its investor relations email address is [email protected] The official website for Windtree Therapeutics is www.windtreetx.com. Learn More about contacing Windtree Therapeutics investor relations.